These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 32198274)

  • 1. The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Cegielski JP; Nahid P; Sotgiu G
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 32198274
    [No Abstract]   [Full Text] [Related]  

  • 2. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis.
    Kendall EA; Fojo AT; Dowdy DW
    Lancet Respir Med; 2017 Mar; 5(3):191-199. PubMed ID: 27989591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.
    Lan NTN ; Lademarco MF; Binkin NJ; Tung LB; Quy HT; Cĵ NV
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):575-8. PubMed ID: 11409587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis.
    Sotgiu G; Migliori GB
    Lancet Respir Med; 2017 Mar; 5(3):159-161. PubMed ID: 27989590
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TB Alliance regimen development for multidrug-resistant tuberculosis.
    Murray S; Mendel C; Spigelman M
    Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Chesov D; Ciobanu N; Lange C; Heyckendorf J; Crudu V
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025881
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antitubercular chemotherapy].
    Jouveshomme S; Dautzenberg B
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the best regimen to treat isoniazid-resistant tuberculosis.
    Migliori GB; Tiberi S; Sotgiu G
    Lancet Respir Med; 2018 Apr; 6(4):233-235. PubMed ID: 29595499
    [No Abstract]   [Full Text] [Related]  

  • 11. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital.
    Weltman AC; Rose DN
    Arch Intern Med; 1994 Oct; 154(19):2161-7. PubMed ID: 7944836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Multidrug'-resistant tuberculosis. It is time to focus on the private sector of medicine.
    Sbarbaro JA
    Chest; 1997 May; 111(5):1149-51. PubMed ID: 9149557
    [No Abstract]   [Full Text] [Related]  

  • 13. Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?
    Tiberi S; D'Ambrosio L; Centis R; Migliori GB
    Int J Infect Dis; 2017 Dec; 65():133-134. PubMed ID: 29122690
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chinese expert consensus on multidrug-resistant tuberculosis and Rifampicin-resistant tuberculosis treatment].
    Chinese Society of Tuberculosis of Chinese Medical Association
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):733-749. PubMed ID: 31594107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Munoz-Torrico M; Salazar MA; Millán MJM; Martínez Orozco JA; Narvaez Diaz LA; Segura Del Pilar M; Visca D; D'Ambrosio L; Centis R; Migliori GB
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29567721
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Barry PM; Lowenthal P; True L; Henry L; Schack G; Wendorf K; Flood J; Shah N
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1488-1489. PubMed ID: 28665681
    [No Abstract]   [Full Text] [Related]  

  • 17. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
    Skevaki CL; Kafetzis DA
    Paediatr Drugs; 2005; 7(4):219-34. PubMed ID: 16117559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    Varaine F; Guglielmetti L; Mitnick CD
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1490-1491. PubMed ID: 28715258
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
    van Leth F; Günther G; Hoffmann H; Lange C;
    Am J Respir Crit Care Med; 2017 Dec; 196(11):1489-1490. PubMed ID: 28715229
    [No Abstract]   [Full Text] [Related]  

  • 20. Surgical management of multidrug-resistant tuberculosis.
    Sasano S; Yamamoto H; Otsuka T; Fujita A; Onuki T; Nitta S
    Jpn J Thorac Cardiovasc Surg; 2001 Feb; 49(2):141-4. PubMed ID: 11257774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.